Predicted protein targets (top 10)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | LMNA | P02545 | 1/20 | 0.46 |
| ▸ | RPA1 | P27694 | 1/20 | 0.45 |
| ▸ | CNR2 | P34972 | 6/20 | 0.43 |
| ▸ | ALDH1A1 | P00352 | 1/20 | 0.41 |
| ▸ | MARS1 | P56192 | 5/20 | 0.41 |
| ▸ | CNR1 | P21554 | 4/20 | 0.41 |
| ▸ | KDM4E | B2RXH2 | 1/20 | 0.40 |
| ▸ | MAPT | P10636 | 1/20 | 0.40 |
| ▸ | GABRA2 | P47869 | 1/20 | 0.39 |
| ▸ | GABRB2 | P47870 | 1/20 | 0.39 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL5768706 | 0.86 | KDM4E (0.52) | CNR2CNR1KDM4EMAPTGABRA2 | |
| SCHEMBL5768629 | 0.85 | LMNA (0.40) | LMNARPA1CNR2ALDH1A1MARS1 | |
| SCHEMBL6766465 | 0.82 | CNR2 (0.59) | CNR2CNR1 | |
| SCHEMBL7047587 | 0.81 | LMNA (0.46) | LMNARPA1CNR2ALDH1A1CNR1 | |
| SCHEMBL6765998 | 0.80 | CNR2 (0.45) | CNR2CNR1 | |
| SCHEMBL6765994 | 0.79 | CNR1 (0.48) | LMNACNR2ALDH1A1CNR1 | |
| SCHEMBL6771584 | 0.78 | CNR1 (0.54) | CNR2CNR1 | |
| SCHEMBL5765998 | 0.76 | CNR2 (0.54) | CNR2CNR1 | |
| SCHEMBL6776605 | 0.74 | KDM4E (0.40) | CNR1KDM4EMAPT | |
| SCHEMBL5767346 | 0.74 | CNR2 (0.47) | CNR2CNR1 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 2 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20040235926-A1 | Cannabinoid receptor ligands and uses thereof | PFIZER INC. | 2004-11-25 | — | — | US | claimed |
| US-20040235926-A1 | Cannabinoid receptor ligands and uses thereof | PFIZER INC. | 2004-11-25 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20040235926-A1 | Cannabinoid receptor ligands and uses thereof | CNR1, CNR2, GPR18 | LMNA 3194/4885RPA1 4560/4885CNR2 2/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.